D A Ahlquist

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Molecular detection of colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 138:2127-39. 2010
  2. doi request reprint The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 10:272-7.e1. 2012
  3. ncbi request reprint Next-generation stool DNA test accurately detects colorectal cancer and large adenomas
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 142:248-56; quiz e25-6. 2012
  4. ncbi request reprint Stool screening for colorectal cancer: evolution from occult blood to molecular markers
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Chim Acta 315:157-68. 2002
  5. ncbi request reprint Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel
    D A Ahlquist
    Division of Gastroenterology and Hepatology, Department of Biostatistics, and Division of Molecular Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1219-27. 2000
  6. ncbi request reprint Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
  7. ncbi request reprint Optimization of CT colonography technique: prospective trial in 180 patients
    J G Fletcher
    Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Radiology 216:704-11. 2000
  8. ncbi request reprint Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis
    D H Johnson
    Divsion of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 39:1408-17. 2014
  9. ncbi request reprint Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 79:293-8. 2000
  10. ncbi request reprint Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative
    R S Wooten
    Department of Medicine, Mayo Clinic, Rochester, MN 55905
    Lasers Surg Med 8:294-300. 1988

Research Grants

  1. Colorectal Cancer Screening: Fecal Blood vs DNA
    David Ahlquist; Fiscal Year: 2004

Collaborators

Detail Information

Publications36

  1. doi request reprint Molecular detection of colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 138:2127-39. 2010
    ..This review addresses the biological rationale, technical advances, recent clinical performance data, and remaining issues with molecular screening for colorectal cancer...
  2. doi request reprint The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 10:272-7.e1. 2012
    ..We compared the sensitivities of a multimarker test for stool DNA (sDNA) and a plasma test for methylated septin 9 (SEPT9) in identifying patients with large adenomas or CRC...
  3. ncbi request reprint Next-generation stool DNA test accurately detects colorectal cancer and large adenomas
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 142:248-56; quiz e25-6. 2012
    ..We assessed colorectal neoplasm detection by a next-generation sDNA test and effects of covariates on test performance...
  4. ncbi request reprint Stool screening for colorectal cancer: evolution from occult blood to molecular markers
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Chim Acta 315:157-68. 2002
    ..Participation rates for colorectal cancer screening remain low due, in part, to perceived discomfort, potential harm, and high costs with available tools...
  5. ncbi request reprint Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel
    D A Ahlquist
    Division of Gastroenterology and Hepatology, Department of Biostatistics, and Division of Molecular Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 119:1219-27. 2000
    ..We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without...
  6. ncbi request reprint Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
    ..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
  7. ncbi request reprint Optimization of CT colonography technique: prospective trial in 180 patients
    J G Fletcher
    Department of Diagnostic Radiology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Radiology 216:704-11. 2000
    ..To assess the added benefits of prone positioning in addition to supine positioning and oral iodinated contrast medium for help in the detection of colonic polyps at computed tomographic (CT) colonography...
  8. ncbi request reprint Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis
    D H Johnson
    Divsion of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 39:1408-17. 2014
    ..While sessile serrated polyp (SSP) is a known cancer precursor, serrated epithelial changes (SEC) are of uncertain prevalence and neoplastic risk...
  9. ncbi request reprint Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 79:293-8. 2000
    ..In particular, the relative risk for cancer in females with IMMP was significantly increased, as is true in females with PJS. However, LKB1 mutations did not contribute to the development of IMMP in the patients tested...
  10. ncbi request reprint Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative
    R S Wooten
    Department of Medicine, Mayo Clinic, Rochester, MN 55905
    Lasers Surg Med 8:294-300. 1988
    ..Other HpD-related complications included skin hyperpigmentation, ocular discomfort, pruritus, pain at injection site, and urticaria. CP and the restrictive measures to avoid it represent major disadvantages of the clinical use of HpD...
  11. pmc Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
    J B Kisiel
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 37:546-54. 2013
    ..Current approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD-CRN) are suboptimal...
  12. ncbi request reprint CT colonography without cathartic preparation: feasibility study
    M R Callstrom
    Department of Diagnostic Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Radiology 219:693-8. 2001
    ..Sensitivity for polyp detection in patients with adequate stool labeling approaches the sensitivity for polyp detection in prepared colons...
  13. ncbi request reprint A search for germline APC mutations in early onset colorectal cancer or familial colorectal cancer with normal DNA mismatch repair
    L A Boardman
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genes Chromosomes Cancer 30:181-6. 2001
    ..All appeared to be polymorphisms present in similar proportions in an average-risk population. We conclude that germline APC mutations do not account for familial MSS (stable microsatellite) CRC associated with few synchronous polyps...
  14. ncbi request reprint Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis
    P S Kamath
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 118:905-11. 2000
    ..The response of gastric mucosal lesions in cirrhotic patients with portal hypertension, namely, portal hypertensive gastropathy (PHG) and gastric vascular ectasia (GVE), to transjugular intrahepatic portosystemic shunts (TIPS) is not known...
  15. ncbi request reprint Localization of hematoporphyrin. Derivative to human colorectal cancer
    R S Wooten
    Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota 55905
    Cancer 64:1569-76. 1989
    ..6 microgram/g versus 0.1 microgram/g, P less than 0.001). The authors conclude that HpD preferentially localizes to human colorectal cancer and this is relevant to the photodetection and phototherapy of colorectal neoplasia...
  16. ncbi request reprint Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences
    Thomas M Gluecker
    Department of Radiology, Mayo Clinic Rochester, 200 First Street SW, MN 55905, USA
    Radiology 227:378-84. 2003
    ..To prospectively assess and compare perceptions of and preferences for computed tomographic (CT) colonography, colonoscopy, and double-contrast barium enema examination (DCBE) by asymptomatic patients undergoing colorectal cancer screening...
  17. ncbi request reprint Stool-based DNA tests for colorectal cancer: clinical potential and early results
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Rev Gastroenterol Disord 2:S20-6. 2002
    ..Large, multicenter, comparative studies addressing the performance of stool-based DNA testing in the general population will soon be completed and will promise to validate the readiness of this approach for widespread application...
  18. ncbi request reprint Colorectal cancer prevention and detection. Introduction
    David A Ahlquist
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterol Clin North Am 31:xi-xii. 2002
  19. ncbi request reprint Highly methylated genes in colorectal neoplasia: implications for screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:2686-96. 2007
    ..Comethylation of these genes is common, and pursuit of complementary markers for methylation-negative neoplasms is a rational strategy to optimize screening sensitivity...
  20. ncbi request reprint A novel method to capture methylated human DNA from stool: implications for colorectal cancer screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Clin Chem 53:1646-51. 2007
    ..Assay of methylated DNA markers in stool is a promising approach for colorectal cancer (CRC) screening. A method to capture hypermethylated CpG islands from stool would enrich target analyte and allow optimal assay sensitivity...
  21. ncbi request reprint A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:1115-9. 2006
    ..This study shows that not all CRCs are associated with increased fecal levels of long DNA. Long DNA degrades with fecal storage, and measures to stabilize this analyte must be considered for optimal use of this marker...
  22. ncbi request reprint Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia
    Paul J Limburg
    Division of Gastroenterology and Hepatology and Department of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:2299-305. 2003
    ..Fecal calprotectin was directly compared to fecal hemoglobin (Hb) and colonoscopy as the existing criterion standards for stool screening and structural evaluation, respectively...
  23. ncbi request reprint DNA integrity as a potential marker for stool-based detection of colorectal cancer
    Kevin A Boynton
    Applied Research Group, EXACT Sciences Corporation, 63 Great Road, Maynard, MA 01754, USA
    Clin Chem 49:1058-65. 2003
    ....
  24. ncbi request reprint Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps
    C Daniel Johnson
    Department of Radiology, Mayo Clinic Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 2:314-21. 2004
    ....
  25. ncbi request reprint Stool screening for colorectal cancer: molecular approaches
    Neal K Osborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 128:192-206. 2005
    ..Further marker discovery and technologic refinements should translate into improved test performance and fuel a continued evolution with this screening approach...
  26. ncbi request reprint Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia
    Neal K Osborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 4:212-8. 2006
    ..This study explored the eyes absent 4 (EYA4) gene promoter methylation in noncolitic colorectal tissues and assessed its discrimination for neoplasia in chronic ulcerative colitis (CUC)...
  27. ncbi request reprint Detection of occult upper gastrointestinal tract bleeding: performance differences in fecal occult blood tests
    Gavin C Harewood
    Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:23-8. 2002
    ..All stool samples were subjected to blinded fecal occult blood determinations with use of the 3 tests...
  28. ncbi request reprint Contrast-enhanced CT colonography in recurrent colorectal carcinoma: feasibility of simultaneous evaluation for metastatic disease, local recurrence, and metachronous neoplasia in colorectal carcinoma
    J G Fletcher
    Department of Radiology, Mayo Clinic, East 2B, 200 First St, S W, Rochester, MN 55905, USA
    AJR Am J Roentgenol 178:283-90. 2002
    ....
  29. ncbi request reprint Second primary colorectal cancer: the consequence of management failure at several potential levels
    Paul J Limburg
    Ann Intern Med 136:335-7. 2002
  30. ncbi request reprint Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 14:830-4. 2005
    ....
  31. ncbi request reprint Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps
    C Daniel Johnson
    Department of Radiology, Mayo Clinic Rochester, 200 First Street S W, Rochester, Minnesota 55905, USA
    Gastroenterology 125:311-9. 2003
    ..This study used a low lesion prevalence population reflective of the screening setting to estimate the sensitivity and specificity of computerized tomographic (CT) colonography for detection of colorectal polyps...
  32. ncbi request reprint Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population
    Thomas M Gluecker
    Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Gastroenterology 124:911-6. 2003
    ....
  33. ncbi request reprint Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus
    Hongzhi Zou
    Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Cancer 116:584-91. 2005
    ..Aberrant promoter methylation appears to functionally silence SFRP gene expression in esophageal adenocarcinoma...
  34. ncbi request reprint Detection of colorectal disease by stool defensin assay: an exploratory study
    Hongzhi Zou
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 5:865-8. 2007
    ..We evaluated the neoplasm specificity of HPN1-3 and their discriminant value as stool markers for CRC...
  35. ncbi request reprint Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study
    Paul J Limburg
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 101:1872-9. 2006
    ..However, existing data are inconsistent. We investigated CRC risks, overall and by anatomic subsite, within a population-based inception cohort of clinically confirmed type 2 DM subjects...
  36. ncbi request reprint Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study
    Amit K Gupta
    Division of General Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Clin Gastroenterol Hepatol 3:150-8. 2005
    ..This study assessed concurrent trends in CRC incidence, presentation, survival, mortality, and polypectomies in Olmsted County, Minnesota...

Research Grants1

  1. Colorectal Cancer Screening: Fecal Blood vs DNA
    David Ahlquist; Fiscal Year: 2004
    ..If the DNA-based test proves to have greater screening accuracy than fecal blood testing, this could translate into more effective cancer control and more efficient use of our limited health care resources. ..